Our Focus
Achelios Therapeutics’ primary focus is the development of “New Therapeutic Entities” (NTE) for the treatment of pain and inflammation by topically delivered medications.
We have solved a problem that has plagued industry participants for years. We can successfully transfer large quantities of active non-steroidal anti-inflammatory drugs (NSAIDs) through the dermis and into the target tissue. Our formulation enhances total permeation of drugs across human skin in a compound-selective manner.
